CereVasc
PrivateLast Round
Series C
Jun 4, 2026
Est. Valuation
$135M
Total Funding Raised
$198.9M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
CereVasc operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series C round in June 2026.
CereVasc is a medical device company that develops minimally invasive endovascular treatments for neurological diseases, including its flagship eShunt System for communicating hydrocephalus.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CereVasc Comparables
Compare CereVasc with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| B. Braun SE | 74% | |
| Integra LifeSciences Holdings Corporation | 73% | |
| Medtronic | 72% |
For institutional investors. Book with your work email.
CereVasc Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 4, 2026 | ||||
| Series B | May 13, 2024 | ||||
| Series A | Jun 9, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CereVasc Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series C, Series B |
| Perceptive Advisors | Series C, Series A, Series B |
| Xontogeny | Series B, Series A |
| Bain Capital, LP | Series B |
| Johnson & Johnson Innovation – JJDC | Series C |
| Johnson & Johnson Innovation - JJDC, Inc. | Series C |
| ATON Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 4, 2026
$85M round led by Piper Sandler & Co.
- May 13, 2024
$70M round led by Bain Capital, LP.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- promotesSep 15, 2026
On Sep 15th '26, CereVasc, Inc. announces that Dan Levangie is set to transition from president and CEO to chairman of the board, where he continues to provide strategic guidance and support during the company's next phase of growth.
- hiresSep 15, 2026
CereVasc, Inc. appoints Tony Kingsley as President and Chief Executive Officer on Sep 15th '26 in Massachusetts, while Dan Levangie transitions to Chairman of the Board and continues providing strategic guidance.
- hiresSep 15, 2026
CereVasc, Inc. appoints Tony Kingsley as President and Chief Executive Officer in Massachusetts on Sep 15th '26, as it prepares for commercial introduction of its eShunt System.
For institutional investors. Book with your work email.
CereVasc Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CereVasc's valuation, stock price, and market status.
Is CereVasc a public or private company?
CereVasc is a private company.
What is the current stock price of CereVasc?
CereVasc is a private company, so its shares have no public market price. Caplight tracks CereVasc's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CereVasc worth (valuation)?
CereVasc's valuation is estimated at $135.0M based on funding round data.
Can I buy CereVasc stock?
CereVasc shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CereVasc's last funding round?
CereVasc's most recent funding round was Series C on June 4, 2026.
Who are the main investors in CereVasc?
Key investors in CereVasc include Bain Capital Life Sciences, Perceptive Advisors, Xontogeny, Bain Capital, LP, ATON Partners.
Will CereVasc IPO soon?
No public IPO plans have been announced for CereVasc.
How can I track CereVasc secondary market activity?
Caplight tracks bids, offers, and trades in CereVasc's shares on secondary markets.